X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (672) 672
Publication (104) 104
Book Chapter (23) 23
Conference Proceeding (11) 11
Book Review (7) 7
Dissertation (6) 6
Trade Publication Article (4) 4
Government Document (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (358) 358
animals (298) 298
virus-like particles (288) 288
humans (268) 268
vlp (241) 241
vaccines (239) 239
immunology (216) 216
vaccine (208) 208
viruses (180) 180
mice (169) 169
female (158) 158
proteins (157) 157
virology (138) 138
medicine, research & experimental (132) 132
infection (129) 129
virus diseases (126) 126
immunization (115) 115
vaccines, virus-like particle - immunology (106) 106
immunogenicity (101) 101
vaccination (101) 101
biotechnology & applied microbiology (99) 99
vlps (97) 97
antibodies, viral - blood (93) 93
antibodies (92) 92
health aspects (91) 91
human papillomavirus (90) 90
virus-like particle (83) 83
allergy and immunology (75) 75
expression (75) 75
immune-responses (75) 75
mice, inbred balb c (74) 74
antigens (73) 73
capsid proteins - immunology (73) 73
analysis (72) 72
dendritic cells (72) 72
article (67) 67
cervical cancer (65) 65
hpv (65) 65
immune response (63) 63
cell line (60) 60
papillomavirus vaccines - immunology (60) 60
capsid proteins - genetics (59) 59
neutralizing antibodies (59) 59
papillomavirus infections - prevention & control (59) 59
infections (58) 58
influenza (58) 58
research (57) 57
microbiology (56) 56
papillomavirus infections (56) 56
protein (55) 55
antibodies, viral - immunology (54) 54
viral vaccines - immunology (54) 54
enzyme-linked immunosorbent assay (52) 52
vaccines, virus-like particle - administration & dosage (51) 51
hiv (50) 50
vaccines, synthetic - immunology (48) 48
biochemistry & molecular biology (47) 47
viral proteins (47) 47
cells (46) 46
virion - immunology (46) 46
pharmacology & pharmacy (45) 45
papillomaviridae - immunology (44) 44
protection (44) 44
genetic vectors (43) 43
peptides (43) 43
biochemical research methods (42) 42
cancer (42) 42
immune system (42) 42
prevention (42) 42
complex mixtures (41) 41
epitopes (41) 41
immunity (41) 41
infectious diseases (41) 41
studies (41) 41
adult (40) 40
cervical-cancer (40) 40
influenza vaccines - immunology (40) 40
insect cells (40) 40
viral antibodies (40) 40
vlp vaccine (40) 40
young-women (40) 40
baculovirus (39) 39
gene expression (39) 39
oncogene proteins, viral - immunology (39) 39
papillomavirus infections - immunology (38) 38
capsid protein (37) 37
virion - genetics (37) 37
antigenic determinants (36) 36
influenza vaccines (36) 36
particles (36) 36
vaccines, virus-like particle - genetics (36) 36
efficacy (35) 35
human-papillomavirus type-16 (34) 34
immunoglobulin g (34) 34
male (34) 34
veterinary sciences (34) 34
human papillomavirus 16 - immunology (33) 33
nanoparticles (33) 33
oncology (33) 33
adolescent (32) 32
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (671) 671
French (8) 8
German (7) 7
Spanish (4) 4
Portuguese (3) 3
Chinese (2) 2
Korean (2) 2
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Human Vaccines & Immunotherapeutics, ISSN 2164-5515, 07/2015, Volume 11, Issue 7, pp. 1689 - 1702
This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of 2 doses of the HPV-16/18 AS04-adjuvanted vaccine... 
y, year(s) | AAHS, aluminum hydroxyphosphate sulfate | CI, confidence interval | PBMC, peripheral blood mononuclear cells | ELISA, enzyme-linked immunosorbent assay | M, month(s) | ELISPOT, enzyme-linked immunosorbent spot assay | human papillomavirus (HPV) vaccines | HPV-6/11/16/18(3D), 3-dose schedule of the HPV-6/11/16/18 vaccine | safety | ANOVA, analysis of variance | female adolescents | 50 | PBNA, pseudovirion-based neutralisation assay | GMT, geometric mean antibody titer | ED | 2D, 2-dose | AS04, Adjuvant System containing 50 µg 3-O-desacyl-4 ′-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 µg Al | CMI, cell-mediated immunity | 3D, 3-dose | ) | SAE, serious adverse event | immunogenicity | HPV, human papillomavirus | IgG, immunoglobulin G | TVC, total vaccinated cohort | 3 | ATP-I, according-to-protocol immunogenicity cohort | effective dose producing 50% response | HPV-16/18(2D), 2-dose schedule of the HPV-16/18 vaccine | IFNγ, interferon | VLP, virus-like particle | administration schedule | GMR, geometric mean titer ratio | EU, ELISA unit | HPV-6/11/16/18(2D), 2-dose schedule of the HPV-6/11/16/18 vaccine | pIMD, potential immune-mediated disease | Administration schedule | Safety | Immunogenicity | Human papillomavirus (HPV) vaccines | Female adolescents | PBNA | TVC | enzyme-linked immunosorbent spot assay | pIMD | CLINICAL-TRIAL | potential immune-mediated disease | OF-STUDY ANALYSIS | ELISA unit | IMMUNOLOGY | NEUTRALIZATION ASSAY | 18(3D) | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | geometric mean antibody titer | BLIND PATRICIA TRIAL | CMI | 2-dose | pseudovirion-based neutralisation assay | AS04 | CERVICAL-CANCER | GMR | PBMC | GMT | MEMORY B-CELLS | according-to-protocol immunogenicity cohort | AAHS | PARTICLE VACCINE | SAE | human papillomavirus | HPV VACCINE | ELISA | ATP-I | month(s) | virus-like particle | 3-dose | geometric mean titer ratio | IgG | 2-dose schedule of the HPV-16 | HPV | 18 vaccine | IFN | 18(2D) | CD154 EXPRESSION | analysis of variance | ANOVA | serious adverse event | total vaccinated cohort | year(s) | ED50 | VLP | YOUNG-WOMEN | Adjuvant System containing 50 mu g 3-O-desacyl-4-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 mu g Al3+) | peripheral blood mononuclear cells | aluminum hydroxyphosphate sulfate | immunoglobulin G | 3-dose schedule of the HPV-6 | HPV-16 | HPV-6 | 2-dose schedule of the HPV-6 | interferon | ELISPOT | enzyme-linked immunosorbent assay | confidence interval | cell-mediated immunity | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - adverse effects | Adjuvants, Immunologic - administration & dosage | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - immunology | Vaccine Potency | Humans | Alphapapillomavirus - immunology | Antibodies, Viral - blood | Immunity, Humoral | Time Factors | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - administration & dosage | Papillomavirus Infections - prevention & control | Adolescent | Papillomavirus Vaccines - adverse effects | Female | Immunization Schedule | Papillomavirus Vaccines - immunology | Child | Immunity, Cellular | Papillomavirus Vaccines - administration & dosage | Antibodies, Neutralizing - blood | Medical and Health Sciences | Basic Medicine | Medicinsk bioteknologi | Medical Biotechnology | Medicin och hälsovetenskap | Immunologi inom det medicinska området | Immunology in the medical area | Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy) | Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci) | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Journal Article
Expert Review of Vaccines, ISSN 1476-0584, 10/2010, Volume 9, Issue 10, pp. 1149 - 1176
Journal Article
EXPERT REVIEW OF VACCINES, ISSN 1476-0584, 10/2010, Volume 9, Issue 10, pp. 1149 - 1176
Journal Article
The Lancet, ISSN 0140-6736, 11/2017, Volume 390, Issue 10108, pp. 2143 - 2159
Primary analyses of a study in young women aged 16–26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52,... 
WORLDWIDE | MEDICINE, GENERAL & INTERNAL | IMPACT | VLP VACCINE | METAANALYSIS | DISEASES | PARTICLE VACCINE | GENOTYPE ATTRIBUTION | INFECTION | LESIONS | Immunoassay | Follow-Up Studies | Human papillomavirus 6 - immunology | Humans | Uterine Cervical Neoplasms - epidemiology | Antibodies, Viral - blood | Dose-Response Relationship, Drug | Young Adult | Vaccination - methods | Patient Safety | Adult | Female | Immunogenicity, Vaccine - immunology | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - immunology | Double-Blind Method | Papillomavirus Infections - epidemiology | Uterine Cervical Neoplasms - prevention & control | Treatment Outcome | Injections, Intramuscular | Patient Compliance - statistics & numerical data | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - administration & dosage | Papillomavirus Infections - prevention & control | Adolescent | Primary Prevention - methods | Uterine Cervical Neoplasms - virology | Papillomaviruses | Clinical trials | Vaccines | Papillomavirus infections | Analysis | Women | Human papillomavirus | Immunization | Immunogenicity | Womens health | Epidemiology | Adenocarcinoma | Slopes | Adjudication | Vaccination | Cytology | Infections | Incidence | Randomization | Histopathology | Motivation | Cervical carcinoma | Safety | Lesions | Deoxyribonucleic acid--DNA | Evaluation | Effectiveness | Invasiveness | Abnormalities | Vagina | Cervix | Biopsy | Cervical cancer | Sexual partners | Cancer
Journal Article
Vaccine, ISSN 0264-410X, 2008, Volume 26, Issue 27, pp. 3395 - 3403
Journal Article
Human Vaccines & Immunotherapeutics, ISSN 2164-5515, 12/2014, Volume 10, Issue 12, pp. 3455 - 3465
We previously reported higher anti-HPV-16 and -18 immune responses induced by HPV-16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month... 
CI, confidence interval | CVS, cervicovaginal secretion | PBMC, peripheral blood mononuclear cells | NOAD, new onset autoimmune disease | 50 μg) adsorbed on aluminum salt (500 μg Al(OH) | ELISA, enzyme-linked immunosorbent assay | GMT, geometric mean titer | NOCD, new onset chronic disease | safety | PBNA, pseudovirion-based neutralization assay | ANOVA, analysis of variance | Cervarix | Gardasil | MSC, medically significant condition | GM, geometric mean | AS04, Adjuvant System containing 3-O-desacyl-4'-monophosphoryl lipid A (MPL | GMR, geometric mean (titer) ratio | SAE, serious adverse event | immunogenicity | HPV, human papillomavirus | IgG, immunoglobulin G | TVC, total vaccinated cohort | effective dose producing 50% response | human papillomavirus | ATP, according-to-protocol | VLP, virus-like particle | nAb(s), neutralizing antibody(ies) | CMI, cell-mediated immune | HPA, Health Protection Agency | Human papillomavirus | Safety | Immunogenicity | CONTROLLED-TRIAL | Cervarix (R) | ASSAY | Gardasil (R) | TYPE-18 | IMMUNOLOGY | SUSTAINED EFFICACY | VLP VACCINE | PARTICLE VACCINE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | INFECTION | YOUNG-WOMEN | Follow-Up Studies | Humans | Middle Aged | Antibodies, Viral - blood | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | CD4-Positive T-Lymphocytes - immunology | Young Adult | B-Lymphocytes - immunology | Adolescent | Papillomavirus Vaccines - adverse effects | Adult | Female | Immunologic Memory | Papillomavirus Vaccines - immunology
Journal Article
Acta Biochimica Polonica, ISSN 0001-527X, 2014, Volume 61, Issue 3, pp. 531 - 539
Journal Article
Journal of Virology, ISSN 0022-538X, 12/2017, Volume 91, Issue 23
Journal Article
Vaccine, ISSN 0264-410X, 2011, Volume 29, Issue 44, pp. 7826 - 7834
Journal Article